山西医科大学学报2012，Vol.43Issue(7)：489-493,5.DOI:10.3969/J.ISSN.1007-6611.2012.07.003
Src酪氨酸激酶抑制剂逆转人胃癌顺铂耐药细胞SGC7901/DDP的作用及机制
Reversal effect and mechanism of Src tyrosine kinase inhibitor on multi-drug resistance in cisplatin-resistant human stomach cancer cell line SGC7901/DDP
摘要
Abstract
Objective To explore the effect of Src tyrosine kinase inhibitor on cisplatin-resistant human stomach cancer cell SGC7901/ DDP and its mechanism. Methods The 4-anilinoquirazoline was used to inhibit Src tyrosine kinase in human stomach cancer SGC7901/DDP cell line. Western blot assay was used to examine the expression of p-Src. MTS assay was used to examine the anti-tumor drug sensitivity. Flow cytometry was used to examine Rhl23 excretion and P-glycoprotein (P-gp) expression in SGC7901/DDP. Results Src tyrosine kinase inhibitor 4-anilinoquirazoline obviously decreased the expression of p-Src. The anti-rumor drug sensitivity increased 1. 52-fold and 3.96-fold,the Rh123 intra-ceuular concentration increased 1.24-fold and 2.64-fold,P-gp expression decreased 65.8% and47.4% in SGC7901/DDP after cultured with 5 μmol/L and 10 μmol/L 4-anilinoquirazoline, respectively. Conclusion Src tyrosine kinase inhibitor 4-anilinoquirazoline could reverse the multidrug resistance of SGC7901/DDP,which may be caused by the reduction of Rhl23 excretion and P-gp expression.关键词
Src酪氨酸激酶抑制剂/SGC7901/DDP/多药耐药/Rh123/P糖蛋白Key words
Src tyrosine kinase inhibitor/ SGC7901/DDP/ multidrug resistance/ Rhl23/ P-glycoprotein分类
医药卫生引用本文复制引用
林伟,陈金坤,邱仙土,陈建新..Src酪氨酸激酶抑制剂逆转人胃癌顺铂耐药细胞SGC7901/DDP的作用及机制[J].山西医科大学学报,2012,43(7):489-493,5.基金项目
福建省莆田市科技局立项基金资助项目(2010S10-9) （2010S10-9）
福建省自然科学基金资助项目(2012J01430) （2012J01430）
